For patients battling chronic hepatitis C (HCV) infection, the advent of direct-acting antivirals (DAAs) in 2014 might have felt like the battle against the debilitating disease had been won. However, as a widely-publicized study released in June made clear, many patients are handed a prescription for DAAs only to find out that getting a prescription is only half the battle.
For some, the biggest challenge is actually getting their treatment costs covered by insurance.
According to the study, which ran in Open Forum Infectious Diseases, insurance companies deny coverage in 35.5% of cases. For those with commercial insurance, the denial rate is even higher.